To the full analysis
Buyback calculator for Ascentage Pharma Group International
Ascentage Pharma Group International stock: key metrics
AAPGAscentage Pharma Group International had an operating margin of −211.1% and a return on invested capital (ROIC) of −32.3% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2016 | 96.6% | −1,495.0% | −1,406.5% |
| 2017 | 100.0% | −2,064.9% | −1,872.9% |
| 2018 | 100.0% | −5,074.8% | −5,072.8% |
| 2019 | 85.6% | −4,014.9% | −10,202.7% |
| 2020 | 84.2% | −5,332.9% | −5,442.6% |
| 2021 | 88.1% | −3,116.6% | −2,803.4% |
| 2022 | 89.5% | −405.2% | −421.0% |
| 2023 | 86.2% | −393.1% | −417.0% |
| 2024 | 97.0% | −37.7% | −41.3% |
| 2025 | 76.4% | −211.1% | −216.5% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2016 | 200.0% | −17.6% | −18.2% |
| 2017 | 89.9% | −20.3% | −20.4% |
| 2018 | 34.1% | −32.9% | −28.1% |
| 2019 | −100.0% | −41.0% | −100.0% |
| 2020 | −80.0% | −40.5% | −39.1% |
| 2021 | −63.4% | −33.4% | −26.6% |
| 2022 | −100.0% | −26.4% | −31.2% |
| 2023 | −100.0% | −90.5% | −37.0% |
| 2024 | −100.0% | −38.9% | −15.5% |
| 2025 | −91.2% | −32.3% | −30.5% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = CN¥6.6683)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 23 Jan 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.